Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 30, 2010 Brian Orelli	RNAi Is On Sale The novel technology looks more promising at these prices.
The Motley Fool July 11, 2007 Brian Orelli	Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note.
The Motley Fool September 24, 2010 Brian Orelli	So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership.
The Motley Fool January 9, 2009 Brian Orelli	Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs?
The Motley Fool February 29, 2008 Brian Orelli	RNAi Works -- Maybe Alnylam presents the first proof of concept that RNAi works in humans, but where's the proof that it cures a disease?
The Motley Fool February 9, 2006 Jason Mac Gurn	RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...
Pharmaceutical Executive July 30, 2007	Tomorrow's Drugs A look at the seven top therapies and technologies vying to deliver the next generation of drugs.
Bio-IT World December 15, 2004 Zachary Zimmerman	Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies.
The Motley Fool May 28, 2008 Brian Orelli	A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs.
The Motley Fool May 18, 2007 Mike Havrilla	Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note.
The Motley Fool June 9, 2009 Brian Orelli	Alnylam Lays Down a Sacrifice Bunt RNAi is still an unproven technology, and there's plenty of chances for it to strike out.
The Motley Fool November 6, 2006 Ralph Casale	Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam.
Managed Care November 2003 Thomas Morrow	Making Sense of Antisense and Interference Treatments that interfere with protein synthesis at the cellular level will soon be debated in medical policy committee meetings.
The Motley Fool December 31, 2009 Brian Orelli	Make Money Even When Drugs Fail Biotech growth potential without as much risk can come from innovations that help drugmakers discover new drugs.
The Motley Fool August 1, 2007 Brian Orelli	RNAi Gets Pumped Up Is a collaboration between RNAi expert Alnylam Pharmaceuticals and medical-device maker Medtronic something investors can endorse?
The Motley Fool October 3, 2011 Brian Orelli	About That Developing Technology... Sangamo's diabetic neuropathy drug, SB-509, fails to impress.
The Motley Fool September 20, 2007 Brian Orelli	A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors?
The Motley Fool March 24, 2008 Brian Orelli	Alnylam Authorizes Again The pharmaceutical's latest patent-licensing deal won't be immediately lucrative.
The Motley Fool October 5, 2006 Ralph Casale	RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
Bio-IT World December 15, 2004 David A. Bumcrot	Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi.
Bio-IT World July 15, 2003 Malorye Branca	Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain.
The Motley Fool October 4, 2007 Billy Fisher	Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note.
Bio-IT World December 15, 2004 Nancy Weil	Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic.
Chemistry World November 12, 2009 Hayley Birch	New drug design looks top Notch against cancer A new type of drug that can block the switching on of certain genes in cancer cells has shown promise in mice.
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool August 31, 2011 Brian Orelli	Antibodies: They're Not Just for Fighting Infection Anymore Therapeutic antibodies have continued to evolve since the first, OKT3, was approved back in 1986. Biotech investors had better pay attention, lest the technology passes them by.
The Motley Fool September 28, 2007 Brian Orelli	RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note.
The Motley Fool August 15, 2006 Ralph Casale	Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities.
BusinessWeek August 16, 2004 Arlene Weintraub	The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near.
Chemistry World June 23, 2015 Derek Lowe	Missing the target There are enzymes that no mustard has ever cut, to steal a phrase from science fiction author James Blish. Phosphatases, the flip side of kinase activity, are a perfect example.
The Motley Fool June 23, 2010 Brian Orelli	A Novel Drug Technology Worth Watching Regulus signs up another microRNA partner.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool September 10, 2007 Brian Orelli	Double Your RNA Pleasure Alnylam and ISIS join together to work on microRNAs. Their joint venture, called Regulus Therapeutics, combines their intellectual property in an effort to advance this new technology. Investors should take note.
The Motley Fool September 26, 2007 Brian Orelli	4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies...
Bio-IT World April 16, 2004 Kevin Davies	The Matrix Revolutions Serenex, a company dedicated to drug discovery, uses a proprietary matrix, or affinity media, to bind purine-binding protiens - a process that could transform the drug discovery business.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
Chemistry World January 27, 2011 Elinor Richards	Diet affects cholesterol drug Copper and zinc in the diet could impair the action of statin drugs, compounds prescribed to lower cholesterol, say US scientists.
Bio-IT World September 11, 2003 Mark D. Uehling	Fishing Chips The next generation of protein microarrays from the likes of Protometrix and Molecular Staging may threaten the early leads of Biacore and Ciphergen -- and work so well that drug companies won't want them.
The Motley Fool September 29, 2011 Brian Orelli	Are HIV Drugmakers Doomed? Generics are a bigger threat than Sangamo for now.
Chemistry World January 19, 2011 Jon Cartwright	Modified protein binders give shortcut to drugs The method, which involves attaching polypeptides to the binders, could help reduce the work required to develop protein binders into safer drugs.
Pharmaceutical Executive October 1, 2008	The other half of an HIV mystery is solved When HIV infects a human immune cell, which of the cell's own genes play a role?
Bio-IT World March 2007 Kevin Davies	Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges.
The Motley Fool November 18, 2010 Travis Hoium	Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam.
The Motley Fool November 24, 2009 Brian Orelli	4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc.
Pharmaceutical Executive December 1, 2005 Ron Feemster	The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc.
Pharmaceutical Executive November 1, 2006	Thoughtleader: Making Things Stick Ambrx has created the "glue" that allows researchers to attach activity-enhancing molecules to amino acids where they couldn't before.
The Motley Fool February 18, 2011 John Keeling	An Inside Look at Biotech Investing, Part 2 More on investing in "baby biotechs."
Chemistry World July 31, 2012 David Bradley	Hydrogels can release drugs one at a time A hydrogel that can be programmed to release different protein drugs one after the other rather than all at once could simplify the delivery of complex therapeutic regimens for various diseases.
Chemistry World January 5, 2007 Victoria Gill	PEG Makes Cheaper Drugs for Developing Countries UK and Indian scientists have embarked on a collaboration to develop a new protein-based treatment for hepatitis C, which they say will provide an affordable drug urgently needed in countries where resources are limited.